These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16293911)

  • 21. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study.
    Andersen G; Hedermann G; Witting N; Duno M; Andersen H; Vissing J
    Brain; 2017 Sep; 140(9):2295-2305. PubMed ID: 29050397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Myotonic Dystrophy Type I patient with Predominant Proximal Muscle Weakness without Action Myotonia- A Case Report and Review of Pathology.
    Wu CI; Chien YY; Lee KY
    Acta Neurol Taiwan; 2021 Sep; 30(3)():113-118. PubMed ID: 34841507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of patients with different forms of myotonia with diphenin and novocainamide].
    Biriukov VB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1976 Sep; 76(9):1333-5. PubMed ID: 1015138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myotonic dystrophy types 1 and 2.
    Ashizawa T; Sarkar PS
    Handb Clin Neurol; 2011; 101():193-237. PubMed ID: 21496635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myotonic dystrophy type 2 and related myotonic disorders.
    Meola G; Moxley RT
    J Neurol; 2004 Oct; 251(10):1173-82. PubMed ID: 15503094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical, humoral and histological studies of a case of myotonic syndrome. On the relation between Thomsen's disease, congenital paramyotonia and myotonic dystrophy].
    VENTO R
    Minerva Pediatr; 1962 Feb; 14():110-20. PubMed ID: 13925342
    [No Abstract]   [Full Text] [Related]  

  • 27. [A case of muscle sodium channelopathy with markedly high value of serum creatine kinase and mild eyelid myotonia].
    Kasama S; Kimura T; Kajiyama K; Takeda M; Takahashi MP; Yoshikawa H
    Rinsho Shinkeigaku; 2011 Feb; 51(2):120-4. PubMed ID: 21404612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myotonia fluctuans. A third type of muscle sodium channel disease.
    Ricker K; Moxley RT; Heine R; Lehmann-Horn F
    Arch Neurol; 1994 Nov; 51(11):1095-102. PubMed ID: 7980103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative myotonia assessment with a commercially available dynamometer in myotonic dystrophy types 1 and 2.
    Horáková M; Horák T; Parmová O; Bednařík J; Voháňka S
    Muscle Nerve; 2019 Apr; 59(4):431-435. PubMed ID: 30575988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N1366S mutation of human skeletal muscle sodium channel causes paramyotonia congenita.
    Ke Q; Ye J; Tang S; Wang J; Luo B; Ji F; Zhang X; Yu Y; Cheng X; Li Y
    J Physiol; 2017 Nov; 595(22):6837-6850. PubMed ID: 28940424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
    Logigian EL; Martens WB; Moxley RT; McDermott MP; Dilek N; Wiegner AW; Pearson AT; Barbieri CA; Annis CL; Thornton CA; Moxley RT
    Neurology; 2010 May; 74(18):1441-8. PubMed ID: 20439846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivation of muscle chloride channel by transposon insertion in myotonic mice.
    Steinmeyer K; Klocke R; Ortland C; Gronemeier M; Jockusch H; Gründer S; Jentsch TJ
    Nature; 1991 Nov; 354(6351):304-8. PubMed ID: 1659665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical, electrophysiologic and pathologic findings in 10 patients with myotonic dystrophy 2.
    Dabby R; Sadeh M; Herman O; Leibou L; Kremer E; Mordechai S; Watemberg N; Frand J
    Isr Med Assoc J; 2011 Dec; 13(12):745-7. PubMed ID: 22332444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes.
    Sansone VA; Brigonzi E; Schoser B; Villani S; Gaeta M; De Ambroggi G; Bandera F; De Ambroggi L; Meola G
    Int J Cardiol; 2013 Sep; 168(2):1147-53. PubMed ID: 23266299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.
    Meola G; Cardani R
    Neurol Sci; 2017 Apr; 38(4):535-546. PubMed ID: 28078562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of mexiletine on transitory depression of compound motor action potential in recessive myotonia congenita.
    Lo Monaco M; D'Amico A; Luigetti M; Desaphy JF; Modoni A
    Clin Neurophysiol; 2015 Feb; 126(2):399-403. PubMed ID: 25065301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic approaches to the nosology of muscular disease: myotonias and similar diseases.
    Becker PE
    Birth Defects Orig Artic Ser; 1971 Feb; 7(2):52-62. PubMed ID: 5293617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expert opinion on mexiletine treatment in adult patients with myotonic dystrophy.
    Wahbi K; Bassez G; Duchateau J; Salort-Campana E; Vicart S; Desaphy JF; Labombarda F; Sellal JM; Deharo JC
    Arch Cardiovasc Dis; 2024; 117(6-7):450-456. PubMed ID: 38677940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Thomsen myotonia congenita and strabismus: recording saccades in myotonic diseases].
    Spire M; Tilikete C; Habault C; Vial JC; Kodjikian L; Grange JD
    J Fr Ophtalmol; 2006 Mar; 29(3):271-80. PubMed ID: 16557171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myotonic dystrophy: emerging mechanisms for DM1 and DM2.
    Cho DH; Tapscott SJ
    Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.